Jorge L. Jimenez-Macias

This study identifies a 12-gene BTB signature, shows CDH5 as a core component, and demonstrates that BIA disrupts the BTB to enhance chemotherapy delivery and efficacy in GBM.

This paper develops a high-throughput BTB assembloid model to study glioblastoma-neurovascular interactions and therapeutic responses, finding that BTB disruption correlates with increased tumor invasiveness and drug resistance.

This study identifies Nogo-A as an onco-fetal protein that inhibits glioma vascularization and growth through VEGF-Notch-Hippo-metabolic signaling in human and mouse models.